Fresenius Helios has published initial results from a study of all COVID-19 patients admitted to Helios hospitals in Germany that has been conducted since the start of the pandemic: Two of every three COVID-19 patents in intensive care in Germany require mechanical ventilation. One-third of ventilated intensive care patients die, compared with one-quarter of non-ventilated intensive care patients. This shows that the clinical course of COVID-19 patients in Germany is as poor as in countries hit harder by the pandemic such as Italy, France, the United Kingdom and Belgium. Helios, supported by the Brandenburg Medical School, started in February to collect and analyze data on COVID-19 patents treated in the Helios’ 86 German hospitals. These and additional findings that Helios makes from the study are expected to help in the development of a treatment for the virus.
Fresenius Helios has published initial results from a study of all COVID-19 patients admitted to Helios hospitals in Germany that has been conducted since the start of the pandemic: Two of every three COVID-19 patents in intensive care in Germany require mechanical ventilation. One-third of ventilated intensive care patients die, compared with one-quarter of non-ventilated intensive care patients. This shows that the clinical course of COVID-19 patients in Germany is as poor as in countries hit harder by the pandemic such as Italy, France, the United Kingdom and Belgium. Helios, supported by the Brandenburg Medical School, started in February to collect and analyze data on COVID-19 patents treated in the Helios’ 86 German hospitals. These and additional findings that Helios makes from the study are expected to help in the development of a treatment for the virus.
Fresenius Helios is acquiring three hospitals and four connected medical care centers in the western German cities of Duisburg and Krefeld from the Malteser humanitarian aid group. The facilities have a total of 870 beds, and sales last year were about €160 million. Approximately 2,000 employees treat about 35,000 patients annually at the two locations.
The two Malteser Hospitals in Duisburg cover specialty areas including general surgery; internal medicine; ears, nose and throat medicine; oral and maxillofacial surgery, and geriatrics. Special expertise in hematological oncology is offered. At the Malteser Hospital in Krefeld, a comprehensive range of medical services includes oral and maxillofacial surgery, general surgery and internal medicine as the main specialty areas.
Dr. Francesco De Meo, who is responsible for Helios on the Fresenius Management Board, said: “We welcome the opportunity to acquire three additional Malteser hospitals just shortly after acquiring their hospital in Bonn. When they’re combined with our existing facilities, we will be able to offer the people of this region even better healthcare, tailored to their individual needs and with inpatient and outpatient care that go hand in hand. We are very much looking forward to working with our new colleagues.”
Fresenius Helios expects the acquisition, which is subject to approval by the German antitrust authorities, to close in the fourth quarter of this year. The three hospitals in Duisburg and Krefeld, along with the Malteser Hospital in Bonn, will be integrated into Helios Region West, where Helios already operates 18 acute care hospitals, a rehabilitation clinic and a number of medical care centers.
With approximately 18,000 employees, Helios treats some 300,000 inpatients annually in the region. The company is one of the largest healthcare employers in North Rhine-Westphalia, where Duisburg and Krefeld are situated, and the adjoining state of Lower Saxony.
The parties have agreed not to disclose the purchase price. The acquisition will be accretive to Group earnings starting in 2021.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Helios is acquiring three hospitals and four connected medical care centers in the western German cities of Duisburg and Krefeld from the Malteser humanitarian aid group. The facilities have a total of 870 beds, and sales last year were about €160 million. Approximately 2,000 employees treat about 35,000 patients annually at the two locations.
The two Malteser Hospitals in Duisburg cover specialty areas including general surgery; internal medicine; ears, nose and throat medicine; oral and maxillofacial surgery, and geriatrics. Special expertise in hematological oncology is offered. At the Malteser Hospital in Krefeld, a comprehensive range of medical services includes oral and maxillofacial surgery, general surgery and internal medicine as the main specialty areas.
Dr. Francesco De Meo, who is responsible for Helios on the Fresenius Management Board, said: “We welcome the opportunity to acquire three additional Malteser hospitals just shortly after acquiring their hospital in Bonn. When they’re combined with our existing facilities, we will be able to offer the people of this region even better healthcare, tailored to their individual needs and with inpatient and outpatient care that go hand in hand. We are very much looking forward to working with our new colleagues.”
Fresenius Helios expects the acquisition, which is subject to approval by the German antitrust authorities, to close in the fourth quarter of this year. The three hospitals in Duisburg and Krefeld, along with the Malteser Hospital in Bonn, will be integrated into Helios Region West, where Helios already operates 18 acute care hospitals, a rehabilitation clinic and a number of medical care centers.
With approximately 18,000 employees, Helios treats some 300,000 inpatients annually in the region. The company is one of the largest healthcare employers in North Rhine-Westphalia, where Duisburg and Krefeld are situated, and the adjoining state of Lower Saxony.
The parties have agreed not to disclose the purchase price. The acquisition will be accretive to Group earnings starting in 2021.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Helios Germany has published its first sustainability report. Oriented to the internationally established standards of the Global Reporting Initiative, this 60-page document outlines the four main target groups and areas that Germany’s largest private hospital operator has defined for its sustainability strategy: Patients, employees, the environment and compliance. Along with numerous statistics and examples from Helios Germany hospitals, the report sets out the company’s goals for its future development. Titled ”Für eine gesunde Zukunft” (toward a healthy future), the report is now available in German on www.helios-gesundheit.de. An English version will be published soon.
Helios Germany has published its first sustainability report. Oriented to the internationally established standards of the Global Reporting Initiative, this 60-page document outlines the four main target groups and areas that Germany’s largest private hospital operator has defined for its sustainability strategy: Patients, employees, the environment and compliance. Along with numerous statistics and examples from Helios Germany hospitals, the report sets out the company’s goals for its future development. Titled ”Für eine gesunde Zukunft” (toward a healthy future), the report is now available in German on www.helios-gesundheit.de. An English version will be published soon.
Fresenius Helios is acquiring the Malteser Hospital (“MKHB”) in the western German city of Bonn. The 400-bed acute care hospital, with approximately 750 employees, treats approximately 13,000 patients annually. Its sales last year were about €66 million. Along with the hospital, Fresenius Helios will acquire two medical centers and a pharmacy with attached logistics center.
The MKHB offers a wide range of medical services, with specialties in general surgery, pulmonology and oncology, including palliative care. With certified centers for prostate, intestinal and lung cancers, it will superbly complement the existing Helios hospital in the neighboring city of Siegburg, which specializes in cardiovascular medicine and oncology.
Dr. Francesco De Meo, who is responsible for Helios on the Fresenius Management Board, said: “We are looking forward to working with the new colleagues, who will greatly strengthen our Helios team in North Rhine-Westphalia. With its medical offering, the MKHB is an outstanding fit for us and for our strategy of building specialized centers within regional clusters. Together with our existing facilities, we will be able to offer patients in this densely populated region even better medicine, tailored to meet their needs and all from a single provider.”
Fresenius Helios expects the acquisition, which is subject to approval by the German antitrust authorities, to close in the third quarter of this year. Following the closing, MKHB will be integrated into Helios Region West, which already includes 18 acute care hospitals, a rehabilitation clinic in Duisburg, several medical centers and three maximum care hospitals – in Duisburg and Krefeld, as well as the Helios University Hospital Wuppertal. Helios treats some 300,000 inpatients annually in the region, and is one of the largest healthcare employers in North Rhine-Westphalia and the adjoining state of Lower Saxony.
The seller is the Malteser humanitarian aid group. The parties have agreed not to disclose the purchase price. The acquisition will be accretive to Group earnings starting in 2021.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Helios is acquiring the Malteser Hospital (“MKHB”) in the western German city of Bonn. The 400-bed acute care hospital, with approximately 750 employees, treats approximately 13,000 patients annually. Its sales last year were about €66 million. Along with the hospital, Fresenius Helios will acquire two medical centers and a pharmacy with attached logistics center.
The MKHB offers a wide range of medical services, with specialties in general surgery, pulmonology and oncology, including palliative care. With certified centers for prostate, intestinal and lung cancers, it will superbly complement the existing Helios hospital in the neighboring city of Siegburg, which specializes in cardiovascular medicine and oncology.
Dr. Francesco De Meo, who is responsible for Helios on the Fresenius Management Board, said: “We are looking forward to working with the new colleagues, who will greatly strengthen our Helios team in North Rhine-Westphalia. With its medical offering, the MKHB is an outstanding fit for us and for our strategy of building specialized centers within regional clusters. Together with our existing facilities, we will be able to offer patients in this densely populated region even better medicine, tailored to meet their needs and all from a single provider.”
Fresenius Helios expects the acquisition, which is subject to approval by the German antitrust authorities, to close in the third quarter of this year. Following the closing, MKHB will be integrated into Helios Region West, which already includes 18 acute care hospitals, a rehabilitation clinic in Duisburg, several medical centers and three maximum care hospitals – in Duisburg and Krefeld, as well as the Helios University Hospital Wuppertal. Helios treats some 300,000 inpatients annually in the region, and is one of the largest healthcare employers in North Rhine-Westphalia and the adjoining state of Lower Saxony.
The seller is the Malteser humanitarian aid group. The parties have agreed not to disclose the purchase price. The acquisition will be accretive to Group earnings starting in 2021.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Helios has developed a secure and highly effective process for purifying medical protective masks so they can be safely reused. It is being employed for FFP2- and FFP3-type masks, which help protect medical and care personnel who are treating COVID-19 patients. Going well beyond the safety standard set out by the Robert Koch Institute, Germany’s government agency responsible for disease control and prevention, the process allows the purified masks to be used by any staff member – not just the previous user. Starting immediately, Helios Germany’s hospitals can purify 8,000 masks daily using the process, which was developed with the support of Fresenius Vamed and Fresenius Medical Care. The company has chosen not to commercialize the process and is making complete information about it available online, free of charge.
Fresenius Helios has developed a secure and highly effective process for purifying medical protective masks so they can be safely reused. It is being employed for FFP2- and FFP3-type masks, which help protect medical and care personnel who are treating COVID-19 patients. Going well beyond the safety standard set out by the Robert Koch Institute, Germany’s government agency responsible for disease control and prevention, the process allows the purified masks to be used by any staff member – not just the previous user. Starting immediately, Helios Germany’s hospitals can purify 8,000 masks daily using the process, which was developed with the support of Fresenius Vamed and Fresenius Medical Care. The company has chosen not to commercialize the process and is making complete information about it available online, free of charge.